Literature DB >> 21137056

Non-alcoholic fatty liver disease proteomics.

Eva Rodríguez-Suárez1, Antonio M Duce, Juan Caballería, Félix Martínez Arrieta, Estefanía Fernández, Carolina Gómara, Nere Alkorta, Usue Ariz, M Luz Martínez-Chantar, Shelly C Lu, Felix Elortza, José M Mato.   

Abstract

PURPOSE: Non-alcoholic fatty liver disease (NAFLD) is an important cause of chronic liver injury that has gained concern in clinical hepatology. The principal aim of this study was to find differences in protein expression between patients with NAFLD and healthy controls. EXPERIMENTAL
DESIGN: Changes in protein expression of liver samples from each of the three groups of subjects, controls, non-alcoholic steatosis, and non-alcoholic steatohepatitis (NASH), were analyzed by DIGE combined with MALDI TOF/TOF analysis, a proteomic approach that allows to compare hundreds of proteins simultaneously.
RESULTS: Forty-three proteins exhibiting significant changes (ratio ≥1.5, p<0.05) were characterized, 22 comparing steatosis samples versus control samples and 21 comparing NASH versus control samples. Ten of these proteins were further analyzed by Western blot in tissue samples to confirm the observed changes of protein expression using DIGE. The proteins validated were further tested in serum samples of different cohorts of patients. CONCLUSIONS AND CLINICAL RELEVANCE: Following this approach we identified two candidate markers, carbamoyl phosphate synthase 1 and 78  kDa glucose-regulated protein, differentially expressed between control and NASH. This proteomics approach demonstrates that DIGE combined with MALDI TOF/TOF and Western blot analysis of tissue and serum samples is a useful approach to identify candidate markers associated with NAFLD, resulting in proteins whose level of expression can be correlated to a disease state.
Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21137056      PMCID: PMC3040121          DOI: 10.1002/prca.200900119

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  47 in total

1.  A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease.

Authors:  Zobair M Younossi; Ancha Baranova; Katharine Ziegler; Luca Del Giacco; Karen Schlauch; Timothy L Born; Hazem Elariny; Francesco Gorreta; Amy VanMeter; Abraham Younoszai; Janus P Ong; Zachary Goodman; Vikas Chandhoke
Journal:  Hepatology       Date:  2005-09       Impact factor: 17.425

2.  In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.

Authors:  Anna Wieckowska; Nizar N Zein; Lisa M Yerian; A Rocio Lopez; Arthur J McCullough; Ariel E Feldstein
Journal:  Hepatology       Date:  2006-07       Impact factor: 17.425

3.  Identification of early proteomic markers for hepatic steatosis.

Authors:  G Meneses-Lorente; A Watt; K Salim; S J Gaskell; Nagaraja Muniappa; Jeffrey Lawrence; P C Guest
Journal:  Chem Res Toxicol       Date:  2006-08       Impact factor: 3.739

4.  Steatosis-induced proteomic changes in liver mitochondria evidenced by two-dimensional differential in-gel electrophoresis.

Authors:  Pierre Douette; Rachel Navet; Pascal Gerkens; Edwin de Pauw; Pierre Leprince; Claudine Sluse-Goffart; Francis E Sluse
Journal:  J Proteome Res       Date:  2005 Nov-Dec       Impact factor: 4.466

5.  Breath biomarkers and non-alcoholic fatty liver disease: preliminary observations.

Authors:  S F Solga; A Alkhuraishe; K Cope; A Tabesh; J M Clark; M Torbenson; P Schwartz; T Magnuson; A M Diehl; T H Risby
Journal:  Biomarkers       Date:  2006 Mar-Apr       Impact factor: 2.658

6.  Cleavage of endoplasmic reticulum proteins in hepatocellular carcinoma: Detection of generated fragments in patient sera.

Authors:  Nicolas Chignard; Sufen Shang; Hong Wang; Jorge Marrero; Christian Bréchot; Samir Hanash; Laura Beretta
Journal:  Gastroenterology       Date:  2006-06       Impact factor: 22.682

7.  Molecular profiling of hepatocellular carcinoma in mice with a chronic deficiency of hepatic s-adenosylmethionine: relevance in human liver diseases.

Authors:  Enrique Santamaría; Javier Muñoz; Joaquín Fernandez-Irigoyen; Laura Sesma; María I Mora; Carmen Berasain; Shelly C Lu; José M Mato; Jesús Prieto; Matías A Avila; Fernando J Corrales
Journal:  J Proteome Res       Date:  2006-04       Impact factor: 4.466

8.  Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values.

Authors:  John M Luk; Chi-Tat Lam; Annie F M Siu; Brian Y Lam; Irene O L Ng; Mei-Yu Hu; Chi-Ming Che; Sheung-Tat Fan
Journal:  Proteomics       Date:  2006-02       Impact factor: 3.984

9.  Proteomic analysis of serum marker proteins in recipient mice with liver cirrhosis after bone marrow cell transplantation.

Authors:  Yuichiro Yokoyama; Shuji Terai; Tsuyoshi Ishikawa; Koji Aoyama; Yohei Urata; Yoshio Marumoto; Hiroshi Nishina; Kazuyuki Nakamura; Kiwamu Okita; Isao Sakaida
Journal:  Proteomics       Date:  2006-04       Impact factor: 3.984

10.  Proteomic characterization of the effects of clofibrate on protein expression in rat liver.

Authors:  Jean-François Léonard; Martine Courcol; Claire Mariet; Aurore Charbonnier; Eric Boitier; Marc Duchesne; Fabienne Parker; Bruno Genet; Françoise Supatto; Ruth Roberts; Jean-Charles Gautier
Journal:  Proteomics       Date:  2006-03       Impact factor: 3.984

View more
  18 in total

Review 1.  Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.

Authors:  Jun Wei Lim; John Dillon; Michael Miller
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 2.  Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date.

Authors:  Somaya Albhaisi; Arun J Sanyal
Journal:  Pharmaceut Med       Date:  2019-12

3.  Hsp90 modulates PPARγ activity in a mouse model of nonalcoholic fatty liver disease.

Authors:  Matthew C Wheeler; Nicholas Gekakis
Journal:  J Lipid Res       Date:  2014-06-13       Impact factor: 5.922

Review 4.  Pathogenesis of nonalcoholic steatohepatitis.

Authors:  Wensheng Liu; Robert D Baker; Tavleen Bhatia; Lixin Zhu; Susan S Baker
Journal:  Cell Mol Life Sci       Date:  2016-02-19       Impact factor: 9.261

5.  Proteomic Profiling of Liver and Plasma in Chronic Ethanol Feeding Model of Hepatic Alcohol Dehydrogenase-Deficient Deer Mice.

Authors:  Kamlesh K Bhopale; Samir M Amer; Lata Kaphalia; Kizhake V Soman; John E Wiktorowicz; Ghulam A Shakeel Ansari; Bhupendra S Kaphalia
Journal:  Alcohol Clin Exp Res       Date:  2017-09-08       Impact factor: 3.455

6.  Liver proteomics in progressive alcoholic steatosis.

Authors:  Harshica Fernando; John E Wiktorowicz; Kizhake V Soman; Bhupendra S Kaphalia; M Firoze Khan; G A Shakeel Ansari
Journal:  Toxicol Appl Pharmacol       Date:  2012-11-29       Impact factor: 4.219

Review 7.  Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive tools-a narrative review.

Authors:  Natalia Rosso; Adam M Stephenson; Pablo J Giraudi; Claudio Tiribelli
Journal:  Ann Transl Med       Date:  2021-04

8.  Serum complement C3f and fibrinopeptide A are potential novel diagnostic biomarkers for non-alcoholic fatty liver disease: a study in Qingdao Twins.

Authors:  Yong-Ning Xin; Ning Geng; Zhong-Hua Lin; Ya-Zhou Cui; Hai-Ping Duan; Mei Zhang; Shi-Ying Xuan
Journal:  PLoS One       Date:  2014-09-24       Impact factor: 3.240

9.  Proteomic analysis of mice fed methionine and choline deficient diet reveals marker proteins associated with steatohepatitis.

Authors:  Su Jin Lee; Jeong Han Kang; Waqas Iqbal; Oh-Shin Kwon
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

10.  Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD.

Authors:  Steven G Pearce; Nirav C Thosani; Jen-Jung Pan
Journal:  Biomark Res       Date:  2013-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.